Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FCSC

Fibrocell Science (FCSC) Stock Price, News & Analysis

Fibrocell Science logo

About Fibrocell Science Stock (NASDAQ:FCSC)

Key Stats

Today's Range
$3.00
$3.00
50-Day Range
$3.00
$3.00
52-Week Range
$1.45
$3.28
Volume
N/A
Average Volume
78,673 shs
Market Capitalization
$29.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.

Receive FCSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter.

FCSC Stock News Headlines

Best Data Science Bootcamps Online In 2024
Science & Tech News
Former Trump advisor releases terrifying warning
Goldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.”
Oramed Pharmaceuticals
See More Headlines

FCSC Stock Analysis - Frequently Asked Questions

Fibrocell Science Inc (NASDAQ:FCSC) released its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $1.30. The business had revenue of $21.79 million for the quarter.

Fibrocell Science shares reverse split on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Neurotrope (NTRP) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/14/2019
Today
11/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FCSC
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-10,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$29.28 million
Optionable
Optionable
Beta
1.67
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:FCSC) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners